Amylyx Pharmaceuticals, Inc.

# Amylyx Pharmaceuticals, Inc.

Amylyx is a clinical-stage pharmaceutical company developing treatments for neurodegenerative diseases and endocrine disorders. The company's primary focus is on rare and orphan conditions with limited therapeutic options. Its lead candidate, avexitide, is a first-in-class GLP-1 receptor antagonist currently in phase 3 trials for post-bariatric hypoglycemia and congenital hyperinsulinism. The company also advances AMX0035, an oral fixed-dose combination of sodium phenylbutyrate and taurursodiol, which is in phase 2 trials for Wolfram syndrome and phase 2b/3 trials for progressive supranuclear palsy. Additional pipeline assets include AMX0114 for amyotrophic lateral sclerosis in phase 1 development and a long-acting GLP-1 receptor antagonist program.

Founded in 2013, Amylyx is headquartered in Cambridge, Massachusetts and employs 123 full-time staff. The company operates as a clinical-stage biotech enterprise without approved marketed products, meaning revenue is limited to research collaborations or milestone payments rather than product sales. The company is publicly listed on Nasdaq and maintains operations in the United States.